Synthesis and Monoamine Oxidase Inhibitory Activities of some 3-(4-Fluorophenyl)-5-aryl-N-substituted-4,5-dihydro-(1H)-pyrazole-1-carbothioamide Derivatives

Abstract

28 new 3-(4-fluorophenyl)-5-aryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives were synthesized and evaluated in vitro for their monoamine oxidase (MAO) A and B inhibitory activity and selectivity. The derivatives substituted by halogen on the fifth position of pyrazole ring, inhibited MAO-A enzyme with a high selectivity index. On the other hand, compounds substituted with 2-naphthyl inhibited MAO-B enzyme with a moderate selectivity index. Docking studies were done to highlight the interactions of the most active derivative with the active site of MAO-A. In addition, in vivo antidepressant and anxiolytic activities of the compounds having selective MAO-A inhibitory effects, were investigated by using Porsolt forced swimming and elevated plus-maze tests respectively. 3-(4-Fluorophenyl)-5-(4-chloro­phenyl)-N-allyl-4,5-dihydro-1H-pyrazole-1-carbothio­amide has antidepressant, 3-(4-fluorophenyl)-5-(4-chlorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide and 3-(4-fluoro­phenyl)-5-(4-bromophenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carbothioamide have anxiolytic activity.

Key words

2-pyrazoline - 4,5-dihydropyrazole - monoamine oxidase - antidepressant - docking

• References

• 1 Wouters J, Moureau F, Evrard G et al. A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action. Bioorg Med Chem 1999; 7: 1683-1693
• 2 Curet O, Damoiseau-Ovens G, Sauvage C et al. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord 1998; 51: 287-303
• 3 Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226-247
• 4 Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295-309
• 5 Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 2006; 147 (Suppl. 01) S287-S296
• 6 Manna F, Chimenti F, Bolasco A et al. Inhibition of amine oxidases activity by 1-acetyl-3, 5-diphenyl-4, 5-dihydro-(1H)-pyrazole derivatives. Bioorg Med Chem Lett 2002; 12: 3629-3633
• 7 Gökhan N, Yeşilada A, Ucar G et al. 1 N Substituted Thiocarbamoyl 3 phenyl 5 thienyl 2 pyrazolines: Synthesis and Evaluation as MAO Inhibitors. Arch Pharm 2003; 336: 362-371
• 8 Chimenti F, Maccioni E, Secci D et al. Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarbamoyl-3, 5-diaryl-4, 5-dihydro-(1 H)-pyrazole Derivatives. J Med Chem 2005; 48: 7113-7122
• 9 Chimenti F, Carradori S, Secci D et al. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3, 5-di (hetero) aryl-4, 5-dihydro-(1H)-pyrazole derivatives. Eur J Med Chem 2010; 45: 800-804
• 10 Palaska E, Aydin F, Uçar G et al. Synthesis and Monoamine Oxidase Inhibitory Activities of 1 Thiocarbamoyl 3, 5 diphenyl 4, 5 dihydro 1H pyrazole Derivatives. Arch Pharm 2008; 341: 209-215
• 11 Senturk K, Tan OU, Ciftci SY et al. Synthesis and evaluation of human monoamine oxidase inhibitory activities of some 3,5-diaryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives. Arch Pharm 2012; 345: 695-702
• 12 Holt A, Sharman DF, Baker GB et al. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 1997; 244: 384-392
• 13 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 14 Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-732
• 15 Porsolt RD, Anton G, Blavet N et al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. European journal of pharmacology 1978; 47: 379-391
• 16 Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987; 92: 180-185
• 17 Son SY, Ma J, Kondou Y et al. Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci 2008; 105: 5739
• 18 Davey W, Tivey DJ. Chalcones and related compounds. Addition of hydrogen cyanide to chalcones. J Chem Soc (Resumed) 1958; 1230-1236
• 19 Mehra HS. Studies on b-(4-Chlorobenzoyl)acrylic Acid. Formation of Chalcones by Meerwein’s Arylation Method anf of Adduct with Various Amines. J Indian Chem Soc 1968; 45: 178-181
• 20 Caille D, Bergis OE, Fankhauser C et al. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 1996; 277: 265-277